betaxolol has been researched along with Chronic Disease in 13 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with placebo, adding betaxolol 20 mg every day to nifedipine (up to 60 mg/day in divided doses) or diltiazem (up to 360 mg/day in divided doses) for a 3-week treatment period in 135 patients with stable angina pectoris significantly (p < 0." | 9.07 | Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. ( Friedman, R; Glasser, SP; Smith, LK; Talibi, T; Weir, EK, 1994) |
| " This finding motivated further studies aimed at determining whether treatment with betaxolol, a highly selective beta(1)-adrenergic receptor antagonist, could ameliorate cocaine withdrawal-induced anxiety." | 7.74 | Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. ( Rudoy, CA; Van Bockstaele, EJ, 2007) |
| "Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina." | 5.27 | Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. ( Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987) |
| "In a prospective, randomized study, nineteen patients with ocular hypertension (n = 14) or chronic open-angle glaucoma (n = 5) were treated with either betaxolol 0." | 5.07 | Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. ( Collignon-Brach, J, 1994) |
| "Compared with placebo, adding betaxolol 20 mg every day to nifedipine (up to 60 mg/day in divided doses) or diltiazem (up to 360 mg/day in divided doses) for a 3-week treatment period in 135 patients with stable angina pectoris significantly (p < 0." | 5.07 | Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. ( Friedman, R; Glasser, SP; Smith, LK; Talibi, T; Weir, EK, 1994) |
| " This finding motivated further studies aimed at determining whether treatment with betaxolol, a highly selective beta(1)-adrenergic receptor antagonist, could ameliorate cocaine withdrawal-induced anxiety." | 3.74 | Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. ( Rudoy, CA; Van Bockstaele, EJ, 2007) |
| "This study examined the effects of beta blockade with betaxolol, a cardioselective, lipid-soluble, beta-adrenergic-blocking agent, on rest and exercise systolic and diastolic left ventricular function in 15 patients, aged 40 to 70 years (mean = 52), with chronic stable angina pectoris." | 3.67 | Effects of beta blockade on systolic and diastolic left ventricular function at rest and during exercise in patients with chronic stable angina pectoris. ( Fernandes, M; Fiorentini, R; Hakki, AH; Heo, J; Iskandrian, AS; Nestico, PF; Schenk, C, 1987) |
| "Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina." | 1.27 | Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. ( Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manoury, PM | 1 |
| Binet, JL | 1 |
| Rousseau, J | 1 |
| Lefèvre-Borg, F | 1 |
| Cavero, IG | 1 |
| Rudoy, CA | 1 |
| Van Bockstaele, EJ | 1 |
| Koh, KK | 2 |
| Kwon, KS | 2 |
| Park, HB | 2 |
| Baik, SH | 2 |
| Park, SJ | 1 |
| Lee, KH | 1 |
| Kim, EJ | 1 |
| Kim, SH | 1 |
| Cho, SK | 2 |
| Kim, SS | 1 |
| Collignon-Brach, J | 1 |
| Glasser, SP | 1 |
| Friedman, R | 1 |
| Talibi, T | 1 |
| Smith, LK | 1 |
| Weir, EK | 1 |
| Song, JH | 1 |
| Park, YS | 1 |
| In, HH | 1 |
| Moon, TH | 1 |
| Park, GS | 1 |
| Lamberti, G | 1 |
| Pignalosa, B | 1 |
| Fusco, R | 1 |
| Pignalosa, G | 1 |
| Di Govanni, A | 1 |
| Sebastiani, A | 1 |
| Gillies, WE | 1 |
| Brooks, AM | 1 |
| Atwood, JE | 1 |
| Myers, J | 1 |
| Quaglietti, S | 1 |
| Grumet, J | 1 |
| Gianrossi, R | 1 |
| Umman, T | 1 |
| Böhler, S | 1 |
| Saubadu, S | 1 |
| Scheldewaert, R | 1 |
| Figulla, HR | 1 |
| Wilhelmus, KR | 1 |
| McCulloch, RR | 1 |
| Gross, RL | 1 |
| Iskandrian, AS | 1 |
| Nestico, PF | 1 |
| Hakki, AH | 1 |
| Heo, J | 1 |
| Fernandes, M | 1 |
| Fiorentini, R | 1 |
| Schenk, C | 1 |
| Kendall, K | 1 |
| Mundorf, T | 1 |
| Nardin, G | 1 |
| Zimmerman, TJ | 1 |
| Hesse, R | 1 |
| Lavin, P | 1 |
7 trials available for betaxolol and Chronic Disease
| Article | Year |
|---|---|
Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Betaxolol; Chronic Disease; Digoxin; Diltiazem; | 1995 |
Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.
Topics: Administration, Topical; Adult; Aged; Betaxolol; Chronic Disease; Female; Glaucoma, Open-Angle; Huma | 1994 |
Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Betaxolol; Chronic Disease; Diltiazem; Double-Blind | 1994 |
Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrilla | 1995 |
Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic | 1997 |
Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Betaxolol; Cardiac Output; Chronic Disease; | 1999 |
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Chronic Disease; Double | 1999 |
6 other studies available for betaxolol and Chronic Disease
| Article | Year |
|---|---|
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Antihypertensive Agents; Betaxolol; Biotra | 1987 |
Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats.
Topics: Adrenergic beta-Antagonists; Amygdala; Animals; Anxiety; Behavior, Animal; Betaxolol; Blotting, West | 2007 |
An in-service investigation of the additive effect of topical adrenergic agonists and beta-blockers.
Topics: Administration, Topical; Adrenergic Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and | 1998 |
Dendritic keratopathy associated with beta-blocker eyedrops.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Betaxolol; Chronic Disease; Corneal Diseases; | 1990 |
Effects of beta blockade on systolic and diastolic left ventricular function at rest and during exercise in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Betaxolol; Chronic Disease; Female; Human | 1987 |
Tolerability of timolol and betaxolol in patients with chronic open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic Disease; Drug Tolerance; Eye; Female; G | 1987 |